Status:
COMPLETED
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
Lead Sponsor:
Takeda
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of t...
Detailed Description
The drug being tested in this study is called TAK-279. TAK-279 is being tested to treat people with moderate to severe plaque psoriasis. The study will enroll approximately 600 patients. Participants...
Eligibility Criteria
Inclusion
- Plaque psoriasis for at least 6 months.
- Moderate to severe disease.
- Candidate for phototherapy or systemic therapy.
Exclusion
- Other forms of psoriasis.
- History of recent infection.
- Prior exposure to TAK-279 or active comparator.
- Other protocol defined inclusion/exclusion criteria apply.
Key Trial Info
Start Date :
November 6 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 22 2025
Estimated Enrollment :
693 Patients enrolled
Trial Details
Trial ID
NCT06088043
Start Date
November 6 2023
End Date
October 22 2025
Last Update
October 24 2025
Active Locations (132)
Enter a location and click search to find clinical trials sorted by distance.
1
Saguaro Dermatology Associates, LLC - Probity - PPDS
Phoenix, Arizona, United States, 85008-3884
2
First OC Dermatology - Fountain Valley
Fountain Valley, California, United States, 92708-3701
3
Center for Dermatology Clinical Research
Fremont, California, United States, 94538-1614
4
UCLA University of California Los Angeles
Los Angeles, California, United States, 90024